Dr. Mandy Leonard, Senior Director of Drug Use Policy and Formulary Management at Cleveland Clinic and Steven Lucio, Senior Principal in Pharmacy Solutions at Vizient discuss their insights on the approval, role, and coverage of Aducanumab, the first drug in a new class approved for Alzheimer’s by the FDA’s accelerated approval process.

Guest speakers:

Steven Lucio, PharmD, BCPS

Moderator:

Show Notes:

[00:47 -3:06] Other factors driving aducanumab formulary decision making

[03:07-6:35] How CMS is managing this medication

[06:36-9:04] What should patients and families know about this medication?

[09:05-12:33] What frontline pharmacists should know about this medication

Links | Resources:

To use Aduhelm or not to use Aduhelm- that is the question…now what is the evidence? Part 1

EMERGE and ENGAGE

American Academy of Neurology statement

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Google Podcasts

Spotify

Stitcher

Android

RSS Feed